---
title: "\"Performance\" Peijia Medical's mid-term loss narrowed to 69.88 million RMB"
description: "PEIJIA-B announced its interim results for the six months ended June, with revenue recorded at RMB 353 million, an increase of 17.3% year-on-year. The loss narrowed from RMB 71.27 million in the same "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/254325131.md"
published_at: "2025-08-24T13:16:11.000Z"
---

# "Performance" Peijia Medical's mid-term loss narrowed to 69.88 million RMB

> PEIJIA-B announced its interim results for the six months ended June, with revenue recorded at RMB 353 million, an increase of 17.3% year-on-year. The loss narrowed from RMB 71.27 million in the same period last year to RMB 69.88 million, with a loss per share of 10 cents. No dividend was declared

PEIJIA-B (09996.HK) announced its interim results for the six months ended June, with revenue recorded at RMB 353 million, an increase of 17.3% year-on-year. The loss narrowed from RMB 71.27 million in the same period last year to RMB 69.88 million, with a loss per share of 10 cents. No dividend was declared

### Related Stocks

- [09996.HK - PEIJIA-B](https://longbridge.com/en/quote/09996.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 沛嘉医疗申请欧盟批准其心脏植入物 | 沛嘉医疗申请欧盟心脏植入物批准 | [Link](https://longbridge.com/en/news/275249808.md) |
| 沛嘉医疗为 GeminiOne TEER 系统提交欧盟 MDR CE 认证注册 | 沛嘉医疗有限公司已提交其 GeminiOne 经导管边缘对边缘修复系统的欧盟医疗器械法规 CE 标志申请，旨在治疗二尖瓣关闭不全。此次提交是与欧洲合作伙伴 HighLife SAS 共同进行的。该产品也正在中国进行监管审查，并已获得美国 F | [Link](https://longbridge.com/en/news/275242474.md) |
| 德康医疗｜8-K：2025 财年 Q4 营收 12.6 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/275807118.md) |
| 凯利服务-B｜8-K：2025 财年 Q4 营收 10.49 亿美元 |  | [Link](https://longbridge.com/en/news/275757285.md) |
| 美股盘前热门交易：凯利服务-B 盘前跌 8.41%；Jiuzi 盘前跌 4.38% | 凯利服务-B 盘前跌 8.41%；Jiuzi 盘前跌 4.38%；TG-17 盘前涨 196.17%；Leifras 盘前涨 38.43%；以星航运盘前涨 35.50%。 | [Link](https://longbridge.com/en/news/276115778.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.